12:02 PM EST - Aptose Biosciences Inc. : Announced that two abstracts on tuspetinib, Aptose’s Phase 1/2 myeloid kinase inhibitor in development for acute myeloid leukemia (AML), have been accepted for poster presentations at the European School of Haematology (ESH) 6th International Conference: Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment, being held October 29-31, in Estoril, Portugal. Aptose Biosciences Inc.
shares T.APS are trading up $0.24 at $3.24.
